Clene Reports Positive CNM-Au8 Results for Multiple Sclerosis at ECTRIMS 2025

Clene Inc. announced presentation of combined REPAIR-MS trial results at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, showing CNM-Au8 significantly improved brain NAD+/NADH ratios, a key marker of energetic capacity, across relapsing and non-active progressive MS patients. The findings demonstrate that CNM-Au8 treatment produced significant changes in brain NAD+ and NADH fractions, with correlations observed between baseline brain energy metabolism and disability, cognition, and motor function outcomes. These results are particularly significant because they suggest CNM-Au8 may address the underlying bioenergetic failure that contributes to multiple sclerosis progression.

The REPAIR-MS trial results presented at ECTRIMS 2025 indicate that CNM-Au8 was safe and well tolerated by patients, reinforcing its potential to slow disease progression by targeting mitochondrial dysfunction. The improvement in brain NAD+/NADH ratios represents a critical advancement in treating neurodegenerative diseases, as this ratio serves as a fundamental indicator of cellular energy production capacity. Multiple sclerosis affects approximately 2.8 million people worldwide, and current treatments primarily focus on managing symptoms rather than addressing the underlying metabolic deficiencies that drive disease progression.

Clene's approach targets the NAD pathway while reducing oxidative stress, representing a novel therapeutic strategy for neurodegenerative conditions. The company's research suggests that improving mitochondrial health and protecting neuronal function could have broad implications for treating other neurological disorders beyond multiple sclerosis. The positive safety profile observed in the REPAIR-MS trial supports further investigation of CNM-Au8's potential applications. Additional information about the company's research can be found at their corporate website.

The correlation between improved brain energy metabolism and clinical outcomes in multiple sclerosis patients provides compelling evidence for CNM-Au8's mechanism of action. These findings come at a time when the neurological therapeutics field is increasingly focusing on metabolic approaches to treating neurodegenerative diseases. The presentation at ECTRIMS 2025, one of the world's largest multiple sclerosis research conferences, lends credibility to Clene's research methodology and results. Investors and researchers can access additional company updates through their newsroom.

Multiple sclerosis remains a challenging condition to treat, with progressive forms of the disease having limited therapeutic options. The REPAIR-MS results suggest that targeting bioenergetic pathways could represent a new frontier in neurological treatment development. The trial's inclusion of both relapsing and progressive MS patients indicates the potential broad applicability of CNM-Au8 across different disease stages. As research continues, these findings may pave the way for more effective treatments that address the fundamental metabolic impairments driving neurodegeneration in multiple sclerosis and related conditions.